129 related articles for article (PubMed ID: 38611058)
1. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.
Cargnello M; Roux PP
Microbiol Mol Biol Rev; 2011 Mar; 75(1):50-83. PubMed ID: 21372320
[TBL] [Abstract][Full Text] [Related]
2. Impact of Conventional and Atypical MAPKs on the Development of Metabolic Diseases.
Kassouf T; Sumara G
Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32872540
[TBL] [Abstract][Full Text] [Related]
3. Role of the Atypical MAPK ERK3 in Cancer Growth and Progression.
Elkhadragy L; Myers A; Long W
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611058
[TBL] [Abstract][Full Text] [Related]
4. ERK3 is transcriptionally upregulated by ∆Np63α and mediates the role of ∆Np63α in suppressing cell migration in non-melanoma skin cancers.
Alshammari ES; Aljagthmi AA; Stacy AJ; Bottomley M; Shamma HN; Kadakia MP; Long W
BMC Cancer; 2021 Feb; 21(1):155. PubMed ID: 33579235
[TBL] [Abstract][Full Text] [Related]
5. Activation loop phosphorylation of ERK3 is important for its kinase activity and ability to promote lung cancer cell invasiveness.
Elkhadragy L; Alsaran H; Morel M; Long W
J Biol Chem; 2018 Oct; 293(42):16193-16205. PubMed ID: 30166347
[TBL] [Abstract][Full Text] [Related]
6. The C-Terminus Tail Regulates ERK3 Kinase Activity and Its Ability in Promoting Cancer Cell Migration and Invasion.
Elkhadragy L; Alsaran H; Long W
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32516969
[TBL] [Abstract][Full Text] [Related]
7. The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness.
Chen M; Myers AK; Markey MP; Long W
J Cell Physiol; 2019 Aug; 234(8):13220-13232. PubMed ID: 30569573
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitinating Enzyme USP20 Regulates Extracellular Signal-Regulated Kinase 3 Stability and Biological Activity.
Mathien S; Déléris P; Soulez M; Voisin L; Meloche S
Mol Cell Biol; 2017 May; 37(9):. PubMed ID: 28167606
[TBL] [Abstract][Full Text] [Related]
9. ERK3 Increases Snail Protein Stability by Inhibiting FBXO11-Mediated Snail Ubiquitination.
Kim SH; Ryu KJ; Hong KS; Kim H; Han H; Kim M; Kim T; Ok DW; Yang JW; Hwangbo C; Kim KD; Yoo J
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201533
[TBL] [Abstract][Full Text] [Related]
10. A de novo missense mutation in MPP2 confers an increased risk of Vogt-Koyanagi-Harada disease as shown by trio-based whole-exome sequencing.
Liu X; Meng J; Liao X; Liu Y; Zhou Q; Xu Z; Yin S; Cao Q; Su G; He S; Li W; Wang X; Wang G; Li D; Yang P; Hou S
Cell Mol Immunol; 2023 Nov; 20(11):1379-1392. PubMed ID: 37828081
[TBL] [Abstract][Full Text] [Related]
11. ERK3 and DGKζ interact to modulate cell motility in lung cancer cells.
Myers AK; Morel M; Gee SH; Hoffmann KA; Long W
Front Cell Dev Biol; 2023; 11():1192221. PubMed ID: 37287450
[TBL] [Abstract][Full Text] [Related]
12. Increased methylation of ZNF671 suppresses tumor progression by promoting MAPK6 transcription in laryngeal carcinoma.
Zhang W; Liu T; Li X; Li T; Ma X; Zhao D; Zhao X
Int J Biol Sci; 2023; 19(8):2443-2457. PubMed ID: 37215982
[No Abstract] [Full Text] [Related]
13. ERK3/MAPK6 dictates CDC42/RAC1 activity and ARP2/3-dependent actin polymerization.
Bogucka-Janczi K; Harms G; Coissieux MM; Bentires-Alj M; Thiede B; Rajalingam K
Elife; 2023 Apr; 12():. PubMed ID: 37057894
[TBL] [Abstract][Full Text] [Related]
14. HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway.
Liang J; Zhao G; Bian Y; Bi G; Sui Q; Zhang H; Shi H; Shan G; Huang Y; Chen Z; Wang L; Zhan C
PeerJ; 2023; 11():e14996. PubMed ID: 36923501
[TBL] [Abstract][Full Text] [Related]
15. CircDNAJC11 interacts with TAF15 to promote breast cancer progression via enhancing MAPK6 expression and activating the MAPK signaling pathway.
Wang B; Chen H; Deng Y; Chen H; Xing L; Guo Y; Wang M; Chen J
J Transl Med; 2023 Mar; 21(1):186. PubMed ID: 36895010
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]